Search - tctmd.com

Displaying 161 - 180 of 477

Sort: Relevancy | Date

Presentation TCT 2018

Managing Aspirin Allergy Before DES Placement

Presenter: Dominick J. Angiolillo, Elmir Omerovic, John A. Bittl

September 23, 2018

Presentation TCT 2018

Consensus: Considerations In The High Bleeding Risk Patient Requiring PCI And Oral Anticoagulant Therapy

Presenter: George D. Dangas, Giuseppe Tarantini, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Presenter: John A. Bittl, C. Michael Gibson, Deepak L. Bhatt

September 23, 2018

Presentation TCT 2018

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

Presenter: John A. Bittl, C. Michael Gibson, Dimitrios Alexopoulos

September 23, 2018

Presentation TCT 2018

The Case for Bivalirudin With Radial (and Femoral) Access

Presenter: John A. Bittl, C. Michael Gibson, Carey D. Kimmelstiel

September 23, 2018

Presentation TCT 2018

Case #1 Introduction: A High Bleeding Risk Patient With Afib And ACS Requiring PCI And Oral Anticoagulant Therapy

Presenter: George D. Dangas, Giuseppe Tarantini, Steven R. Bailey, Giovanni Esposito, Juan F. Granada, Roxana Mehran, Francesco Saia

September 23, 2018

Presentation TCT 2018

The Latest Antithrombotic Data: MATRIX at 1 Year

Presenter: John A. Bittl, C. Michael Gibson, Stephan Windecker

September 23, 2018

Presentation TCT 2018

Switching Dual Antiplatelet Therapy After PCI: Who, When, Why, and How?

Presenter: John A. Bittl, C. Michael Gibson, Matthew J. Price

September 23, 2018

Presentation TCT 2018

Benefits of Pretreatment With Dual Antiplatelet Therapy Prior to PCI in Stable CAD and ACS: Myth or Reality?

Presenter: John A. Bittl, C. Michael Gibson, Giuseppe Tarantini

September 23, 2018

Presentation TCT 2018

Featured Lecture: Does the Polypill Enhance Drug Adherence and Improve Cardiovascular Outcomes?

Presenter: John A. Bittl, C. Michael Gibson, Valentin Fuster

September 23, 2018

Presentation TCT 2018

Featured Lecture: The High-risk Patient: Risk Assessment and Current Recommendations for DAPT and OAC

Presenter: Bagrat Alekyan, Juan F. Granada, Roxana Mehran

September 22, 2018

Presentation TCT 2018

Clinical Trials for Short DAPT: FDA Perspective

Presenter: Christopher J Popma

September 22, 2018

Presentation TCT 2018

The Current Situation of DAPT for Coronary DES in US

Presenter: Mitchell W. Krucoff

September 22, 2018

Presentation TCT 2018

The Current Situation of DAPT for Coronary DES in Japan

Presenter: Hiroyoshi Yokoi

September 22, 2018

Presentation TCT 2018

Case Conclusion

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Presenter: Philip M. Urban, Robert W. Yeh, Stephan Windecker

September 22, 2018

Presentation TCT 2018

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Presenter: Philip M. Urban, Robert W. Yeh, C. Michael Gibson

September 22, 2018

Presentation TCT 2018

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Presenter: Philip M. Urban, Robert W. Yeh, Tullio Palmerini

September 22, 2018

Advertisement

Managing Aspirin Allergy Before DES Placement

Consensus: Considerations In The High Bleeding Risk Patient Requiring PCI And Oral Anticoagulant Therapy

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

The Case for Bivalirudin With Radial (and Femoral) Access

Case #1 Introduction: A High Bleeding Risk Patient With Afib And ACS Requiring PCI And Oral Anticoagulant Therapy

The Latest Antithrombotic Data: MATRIX at 1 Year

Switching Dual Antiplatelet Therapy After PCI: Who, When, Why, and How?

Benefits of Pretreatment With Dual Antiplatelet Therapy Prior to PCI in Stable CAD and ACS: Myth or Reality?

Featured Lecture: Does the Polypill Enhance Drug Adherence and Improve Cardiovascular Outcomes?

Featured Lecture: The High-risk Patient: Risk Assessment and Current Recommendations for DAPT and OAC

Clinical Trials for Short DAPT: FDA Perspective

The Current Situation of DAPT for Coronary DES in US

The Current Situation of DAPT for Coronary DES in Japan

Case Conclusion

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content